StockNews.com Initiates Coverage on Invitae (NYSE:NVTA)

Research analysts at StockNews.com began coverage on shares of Invitae (NYSE:NVTA) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the medical research company’s stock.

Invitae Stock Performance

Shares of NYSE:NVTA opened at $0.00 on Tuesday. The stock has a market capitalization of $267,010.00, a PE ratio of 0.00 and a beta of 1.59. Invitae has a 1 year low of $0.02 and a 1 year high of $0.02. The firm has a fifty day moving average price of $0.01 and a 200 day moving average price of $0.35.

Institutional Investors Weigh In On Invitae

A number of hedge funds have recently bought and sold shares of NVTA. SG Americas Securities LLC bought a new stake in Invitae during the third quarter valued at about $29,000. ARK Investment Management LLC boosted its holdings in Invitae by 2.1% during the third quarter. ARK Investment Management LLC now owns 32,942,606 shares of the medical research company’s stock valued at $19,937,000 after acquiring an additional 679,672 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in Invitae by 24.1% during the third quarter. Harbor Capital Advisors Inc. now owns 224,642 shares of the medical research company’s stock valued at $136,000 after acquiring an additional 43,642 shares during the period. Strs Ohio lifted its stake in shares of Invitae by 46.9% in the third quarter. Strs Ohio now owns 569,800 shares of the medical research company’s stock valued at $344,000 after buying an additional 181,800 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Invitae by 4.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,652,650 shares of the medical research company’s stock valued at $1,000,000 after buying an additional 64,228 shares during the period. 61.28% of the stock is currently owned by institutional investors.

About Invitae

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.